Breaking Down Hainan Haiyao Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Hainan Haiyao is a turnaround opportunity or a high-risk case study? The numbers are stark: revenue plunged to CNY 990.70 million in 2024 (a 33% drop from CNY 1.48 billion) and trailing-12-month sales fell 19.89% through September 2025, while the company reported a dramatic net loss of CNY 1.47 billion in 2024 (loss per share CNY 1.14) and ROE at a troubling -139.83%; balance-sheet stress shows an asset-liability ratio of 93.01% with total debt of CNY 4.81 billion against cash of CNY 448.84 million (net cash -CNY 4.36 billion) and a debt-to-equity ratio of 14.91, even as market sentiment values the firm at CNY 9.89 billion market cap and an enterprise value of CNY 14.77 billion with a P/S of 10.57 and P/B of 27.09 - yet management is pushing into high-tech and clinical fronts (AI logistics, surgical robotics, a Boao medical park) that could reshape future cash flows; read on.

Hainan Haiyao Co., Ltd. (000566.SZ) - Revenue Analysis

• 2024 revenue: CNY 990.70 million - down 33.0% from 2023 (CNY 1.48 billion).
• Nine months to September 30, 2025: CNY 639.68 million vs. CNY 804.73 million in same period 2024.
• Trailing twelve months (ending Sep 2025): revenue down 19.89% year-over-year.
• Market capitalization (Dec 12, 2025): CNY 9.89 billion - a 27.85% decline year-over-year.
• Company attributes revenue decline principally to strategic decisions including investments and mergers & acquisitions.

• Strategic allocation: Management cites investments and M&A as primary causes - these can depress near-term revenue while aiming to re-shape future earnings mix.
• Persistent downward trend: Revenue decline has been consistent over the past five years, increasing investor concern about sustained top-line recovery.
• Operational pressure: A ~20% YoY TTM revenue drop and weaker 9M 2025 results suggest margin compression risk unless cost offset or synergies materialize from investment/M&A activity.
• Valuation impact: A ~28% fall in market cap by Dec 12, 2025 reflects market repricing tied to the revenue contraction and strategic uncertainty.

Hainan Haiyao Co., Ltd. (000566.SZ) - Profitability Metrics

Hainan Haiyao's recent financial trajectory is dominated by large net losses and negative profitability ratios. Key headline figures and trends are summarized below.

• 2024 full-year net loss: CNY 1.47 billion - a 1,332.3% increase in losses vs. 2023.
• Trailing twelve months (ending Sep 2025) net loss: CNY 1.47 billion; loss per share: CNY 1.14.
• Nine-month net loss (ending Sep 30, 2025): CNY 242.31 million, improved from a loss of CNY 295.19 million in the same period of 2024.
• Return on equity (ROE): -139.83% (TTM ending Sep 2025).
• Return on assets (ROA): -6.23% (TTM ending Sep 2025).

For background on the company's history, ownership and business model, see: Hainan Haiyao Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Hainan Haiyao Co., Ltd. (000566.SZ) - Debt vs. Equity Structure

• Leverage intensity: A debt‑to‑equity of 14.91 indicates liabilities exceed equity by a large multiple, concentrating default and refinancing risk on creditors and shareholders.
• Liquidity stress: Current and quick ratios (0.28 and 0.21) are materially below typical industry thresholds (generally >1), signaling near‑term working capital shortfalls.
• Net indebtedness: With CNY 4.81B total debt against CNY 448.84M cash, net debt of ~CNY 4.36B constrains flexibility for capex, R&D, or strategic moves.
• Equity cushion: Book equity of CNY 322.36M (CNY 0.21/share) is thin relative to liabilities, leaving limited loss‑absorbing capacity.
• Interest affordability: Negative interest coverage (-3.63) shows operating income is insufficient to meet interest expenses - a red flag for covenant breaches or restructuring needs.

• Implications for creditors: High asset‑liability ratio (93.01%) increases priority on asset recovery and collateral; lender covenant monitoring should be heightened.
• Implications for shareholders: Substantial dilution or equity write‑downs are possible if deleveraging requires equity injections or debt‑for‑equity swaps.
• Operational constraints: Cash scarcity likely forces cost cutting, asset sales, renegotiation of payables, or accelerated collection efforts to stabilize liquidity.

Hainan Haiyao Co., Ltd. (000566.SZ) - Liquidity and Solvency

Hainan Haiyao shows pronounced liquidity and solvency stress across core metrics, signaling potential short-term funding strain and sustained profitability challenges.

• Current ratio: 0.28 - well below common benchmarks, indicating limited short-term asset coverage for liabilities.
• Quick ratio: 0.21 - confirms low near-cash asset coverage after inventory exclusion.
• Interest coverage ratio: -3.63 - negative operating income relative to finance costs, unable to service interest from operating profit.
• Net cash position: -CNY 4.36 billion - net cash outflow/negative liquidity on the balance sheet.
• ROE: -139.83% - shareholders' equity is generating deeply negative returns.
• ROA: -6.23% - assets are producing negative returns.
• ROIC: -7.10% - invested capital is delivering negative returns after tax and operating costs.

Key near-term risks and considerations for investors:

• Refinancing risk: negative net cash and poor interest coverage raise the probability of needing external financing or restructuring.
• Equity dilution risk: sustained negative ROE may push management toward capital raises that dilute current shareholders.
• Operational turnaround required: negative ROA/ROIC imply operational and/or market issues must be addressed to restore returns.

For more context on shareholder composition and market positioning, see: Exploring Hainan Haiyao Co., Ltd. Investor Profile: Who's Buying and Why?

Hainan Haiyao Co., Ltd. (000566.SZ) - Valuation Analysis

Key valuation metrics for Hainan Haiyao as of December 12, 2025, paint a picture of a high-priced equity with constrained cash generation and relatively low market volatility. Below are the headline figures and their immediate implications for investors.

• Market Capitalization: CNY 9.89 billion (down 27.85% year-over-year)
• Enterprise Value (EV): CNY 14.77 billion
• Price-to-Sales (P/S): 10.57
• Price-to-Book (P/B): 27.09
• Price-to-Free Cash Flow (P/FCF): -149.35 (negative FCF)
• Price-to-Operating Cash Flow (P/OCF): 115.52
• Beta: 0.55

Practical takeaways for investors:

• High P/S and P/B suggest growth expectations or strategic premium; verify revenue growth and margin sustainability.
• Negative FCF and extremely high P/OCF signal cash generation stress-assess working capital trends, capex, and one-time items.
• EV materially above market cap points to leverage or adjustments-check net debt and off‑balance exposures.
• Low beta means lower correlation with index moves; however, valuation risk remains if fundamentals don't improve.
• Cross-reference company history and structural context: Hainan Haiyao Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Hainan Haiyao Co., Ltd. (000566.SZ) - Risk Factors

• High leverage: asset-liability ratio of 93.01% signals that nearly all assets are financed by liabilities, leaving limited equity buffer.
• Extremely leveraged capital structure: debt-to-equity ratio of 14.91 implies liabilities are almost 15x shareholders' equity, amplifying solvency risk.
• Negative cash position: net cash is negative (net debt > 0), increasing short-term liquidity and refinancing risk.
• Very weak profitability: ROE at -139.83% reflects large losses relative to equity, potentially eroding shareholder value.
• Poor asset returns: ROA at -6.23% indicates assets are generating negative returns, diminishing asset efficiency.
• Negative invested capital returns: ROIC at -7.10% shows the company is destroying value on invested capital.

Hainan Haiyao Co., Ltd. (000566.SZ) - Growth Opportunities

• Integration of TCM and modern pharma: advancing proprietary formulations and clinical research pipelines to target chronic and age-related conditions.
• Industrial park build-out: development of an integrated medical industrial park in Boao Hope City, Hainan - slated for completion by mid-2025 - intended to consolidate R&D, manufacturing, and distribution.
• Digital supply-chain transformation: deployment of an AI-powered warehouse management and logistics platform (launched May 2024) to improve inventory turns and fulfilment accuracy.
• Surgical innovation and device R&D: participation in a remote robotic lobectomy (July 2024) and roadmap to introduce minimally invasive surgical robots and smart home-use medical devices.
• Distribution expansion: strategic initiatives to deepen domestic penetration and build global channels for high-end medical product lines.

• R&D scale-up: cross-disciplinary teams combining TCM formulation expertise with digital health and device engineering to accelerate IND/clinical progress.
• Manufacturing consolidation: on-site GMP-capable facilities in Boao to raise gross margin potential via in-house production and lower COGS.
• Supply-chain automation: AI logistics reducing stockouts and expired inventory, improving working capital efficiency (DIO reduction potential of several days to weeks).
• Clinical partnerships and credentials: high-visibility robotic surgery programs provide regulatory and hospital-relationship advantages for device adoption.
• Channel diversification: leveraging hospital, distributor, and direct-to-consumer channels to increase ASP (average selling price) for premium offerings.

• Execution timeline risk: delays in Boao park completion or regulatory approvals for devices could defer revenue recognition.
• Capex and funding: construction and device commercialization require meaningful capex; funding mix (cash, debt, equity) will affect balance sheet metrics.
• Commercial adoption: surgical robots and smart devices face hospital procurement cycles and reimbursement dynamics that can slow market penetration.
• Integration complexity: merging TCM heritage with modern clinical and device pathways requires sustained R&D and regulatory discipline.